Issues in the treatment of bipolar disorder

European Neuropsychopharmacology

Volumn 13, Issue SUPPL. 2, 2003, Pages 37-42

  Kasper, Siegfried ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bipolar disorder; Diagnosis; Lamotrigine; Long term; Treatment

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; LAMOTRIGINE; LITHIUM; NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR; VALPROIC ACID;

ALCOHOL ABUSE; ATTENTION DEFICIT DISORDER; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR MANIA; BORDERLINE STATE; CARDIOTOXICITY; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; DELUSIONAL DISORDER; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY DISEASE; META ANALYSIS; MORBIDITY; MORTALITY; PATIENT COMPLIANCE; PERSONALITY DISORDER; PRIORITY JOURNAL; PROGNOSIS; SCHIZOPHRENIA; SIDE EFFECT; SKIN TOXICITY; SUBSTANCE ABUSE; SUICIDE; SYMPTOMATOLOGY; THYROID DISEASE; TREATMENT OUTCOME; TREMOR; WEIGHT GAIN;

EID: 0042832904     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(03)00076-2     Document Type: Conference Paper

References (71)

1. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition, Text Revision: 2000;American Psychiatric Press, Washington, DC.
2. Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord. 50:1998;143-151.
3. Angst J., Sellaro R. Historical perspectives and natural history of bipolar disorder. Biol Psychiatry. 48:2000;445-457.
4. Asconape J.J. Some common issues in the use of antiepileptic drugs. Semin Neurol. 22:2002;27-39.
5. Balestrieri M., Vampini C., Bellantuono C. Efficacy and safety of novel antipsychotics: a critical review. Hum Psychopharmacol. 15:2000;499-512.
6. Ballenger J.C., Post R.M. Therapeutic effects of carbamazepine in affective illness: a preliminary report. Comm Psychopharmacol. 2:1978;159-175.
7. Bhana N., Perry C.M. Olanzapine: a review of its use in the treatment of bipolar I disorder. CNS Drugs. 15:2001;871-904.
8. Bottlender R., Rudolf D., Strauss A., Moller H.J. Mood-stabilisers reduce the risk of developing antidepressant-induced maniform states in acute treatment of bipolar I depressed patients. J Affect Disord. 63:2001;79-83.
9. Bowden C.L. Strategies to reduce misdiagnosis of bipolar depression. Psychiatr Serv. 52:2001;51-55.
10. Bowden C.L., Brugger A.M., Swann A.C., Calabrese J.R., Janicak P.G., Petty F., Dilsaver S.C., Davis J.M., Rush A.J., Small J.G., Garza-Treviño E.S., Risch S.C., Goodnick P.J., Morris D.D. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA. 271:1994;918-924.
11. Bowden C.L., Calabrese J.R., McElroy S.L., Gyulai L., Wassef A., Petty F., Pope H.G. Jr., Chou J.C., Keck P.E. Jr., Rhodes L.J., Swann A.C., Hirschfeld R.M., Wozniak P.J. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry. 57:2000;481-489.
12. Brady K.T. Difficulties in diagnosis and management of bipolar disorder: three case presentations. J Clin Psychiatry. 61:(Suppl 13):2000;32-37.
13. Brambilla P., Barale F., Soares J.C. Perspectives on the use of anticonvulsants in the treatment of bipolar disorder. Int J Neuropsychopharmacol. 4:2001;421-446.
14. Burgess, S., Geddes, J., Hawton, K., Townsend, E., Jamison, K., Goodwin, G., 2002. Lithium for maintenance treatment of mood disorders (Cochrane Review). The Cochrane Library.
15. Calabrese, J.R., Bowden, C.L., DeVeaugh-Geiis, J., Earl, N.E., Gyulai, L., Sachs, G.S., Montgomery, P., 2001. Lamotrigine demonstrates long-term mood stabilization in manic patients. American Psychiatric Association, May 5-10, NR403.
16. Calabrese J.R., Bowden C.L., Sachs G.S., Ascher J.A., Monaghan E., Rudd G.D. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry. 60:1999;79-88.
17. Calabrese, J.R., Bowden, C.L., Yatham, L.N., Behnke, K., Mehtonen, O.-P., Montgomery, P., Paska, W., Earl, N.E., DeVeaugh-Geiis, J., 2003. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. JAMA (in press).
18. Calabrese J.R., Shelton M.D., Rapport D.J., Kimmel S.E., Elhaj O. Long-term treatment of bipolar disorder with lamotrigine. J Clin Psychiatry. 63:2002;18-22.
19. Calabrese J.R., Suppes T., Bowden C.L., Sachs G.S., Swann A.C., McElroy S.L., Kusumakar V., Ascher J.A., Earl N.L., Greene P.L., Monaghan E.T. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry. 61:2000;841-850.
20. Chen Y.W., Dilsaver S.C. Lifetime rates of suicide attempts among subjects with bipolar and unipolar disorders relative to subjects with other Axis I disorders. Biol Psychiatry. 39:1996;896-899.
21. Chengappa K.N., Gershon S., Levine J. The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder. Bipolar Disord. 3:2001;215-232.
22. Cohn J.B., Collins G., Ashbrook E., Wernicke J.F. A comparison of fluoxetine, imipramine and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol. 4:1989;313-322.
23. Colom F., Vieta E., Martinez-Aran A., Reinares M., Benabarre A., Gasto C. Clinical factors associated with treatment noncompliance in euthymic bipolar patients. J Clin Psychiatry. 61:2000;549-555.
24. Dunner D.L., Fieve R.R. Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry. 30:1974;229-233.
25. Egeland J.A., Blumenthal R.L., Nee J., Sharpe L., Endicott J. Reliability and relationship of various ages of onset criteria for major affective disorder. J Affect Disord. 12:1987;159-165.
26. Faravelli C., Incerpi G. Epidemiology of affective disorders in Florence. Preliminary results. Acta Psychiatr Scand. 72:1985;331-333.
27. Frye M.A., Ketter T.A., Kimbrell T.A., Dunn R.T., Speer A.M., Osuch E.A., Luckenbaugh D.A., Cora-Ocatelli G., Leverich G.S., Post R.M. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol. 20:2000;607-614.
28. Gitlin M.J., Swendsen J., Heller T.L., Hammen C. Relapse and impairment in bipolar disorder. Am J Psychiatry. 152:1995;1635-1640.
29. Goodwin F.K., Jamison K.R. Manic-Depressive Illness. 1990;Oxford University Press, New York.
30. Goodwin F.K. Rationale for long-term treatment of bipolar disorder and evidence for long-term lithium treatment. J Clin Psychiatry. 63:2002;5-12.
31. Henry C., Sorbara F., Lacoste J., Gindre C., Leboyer M. Antidepressant-induced mania in bipolar patients: identification of risk factors. J Clin Psychiatry. 62:2001;249-255.
32. Isometsa E., Henriksson M., Heikkinen M., Lonnqvist J. Suicide after discharge from psychiatric inpatient care. Lancet. 342:1993;1055-1056.
33. ® indications: says it will not pursue a third. Press Release (PR Newswire).
34. Judd L.L., Akiskal H.S., Schettler P.J., Endicott J., Maser J., Solomon D.A., Leon A.C., Rice J.A., Keller M.B. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 59:2002;530-537.
35. Kasper S., Stamenkovic M., Letmaier M., Schreinzer D. Atypical antipsychotics in mood disorders. Int Clin Psychopharmacol. 17:2002;S1-S10.
36. Keck P.E. Jr., McElroy S.L., Strakowski S.M., Bourne M.L., West S.A. Compliance with maintenance treatment in bipolar disorder. Psychopharmacol Bull. 33:1997;87-91.
37. Keck P.E. Jr., Mendlwicz J., Calabrese J.R., Fawcett J., Suppes T., Vestergaard P.A., Carbonell C. A review of randomized, controlled clinical trials in acute mania. J Affect Disord. 59:(Suppl. 1):2000;S31-S37.
38. Keck P.E. Jr., McElroy S.L. Outcome in the pharmacologic treatment of bipolar disorder. J Clin Psychopharmacol. 16:1996;15S-23S.
39. Keck P.E. Jr., McElroy S.L., Nemeroff C.B. Anticonvulsants in the treatment of bipolar disorder. J Neuropsychiatry Clin Neurosci. 4:1992;395-405.
40. Klein D.F. Importance of psychiatric diagnosis in prediction of clinical drug effects. Arch Gen Psychiatry. 16:1967;118-126.
41. Kukopulos A., Reginaldi D., Laddomada P., Floris G., Serra G., Tondo L. Course of the manic-depressive cycle and changes caused by treatment. Pharmakopsychiatr Neuropsychopharmakol. 13:1980;156-167.
42. Kupfer D.J., Frank E., Grochocinski V.J., Cluss P.A., Houck P.R., Stapf D.A. Demographic and clinical characteristics of individuals in a bipolar disorder case registry. J Clin Psychiatry. 63:2002;120-125.
43. Lepine J.P., Lellouch J., Lovell A. Anxiety and depressive disorder in a French population: methodology and preliminary results. Psychiatr Psychobiol. 4:1989;267-274.
44. Lingam R., Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand. 105:2002;164-172.
45. Lyskowski J., Nasrallah H.A., Dunner F.J., Bucher K. A longitudinal survey of side effects in a lithium clinic. J Clin Psychiatry. 43:1982;284-286.
46. Macritchie, K.A.N., Geddes, J.R., Scott, J., Haslam, D.R.S., Goodwin, G.M., 2002. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder (Cochrane Review). The Cochrane Library.
47. Maidment I.D. Gabapentin treatment for bipolar disorders. Ann Pharmacother. 35:2001;1264-1269.
48. Maj M., Magliano L., Pirozzi R., Marasco C., Guarneri M. Validity of rapid cycling as a course specifier for bipolar disorder. Am J Psychiatry. 151:1994;1015-1019.
49. Nemeroff C.B., Evans D.L., Gyulai L., Sachs G.S., Bowden C.L., Gergel I.P., Oakes R., Pitts C.D. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry. 158:2001;906-912.
50. Okuma T., Inanaga K., Otsuki S., Sarai K., Takahashi R., Hazama H., Mori A., Watanabe M. Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: a double-blind controlled study. Psychopharmacology. 66:1979;211-217.
51. Oliver J.M., Simmons M.E. Affective disorders and depression as measured by the Diagnostic Interview Schedule and the Beck Depression Inventory in an unselected adult population. J Clin Psychol. 41:1985;496-576.
52. Oquendo M.A., Waternaux C., Brodsky B., Parsons B., Haas G.L., Malone K.M., Mann J.J. Suicidal behavior in bipolar mood disorder: clinical characteristics of attempters and nonattempters. J Affect Disord. 59:2000;107-117.
53. Pande A.C., Crockatt J.G., Janney C.A., Werth J.L., Tsaroucha G. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord. 2:2000;249-255.
54. Poolsup N., Li Wan Po A., de Oliveira I.R. Systematic overview of lithium treatment in acute mania. J Clin Pharm Ther. 25:2000;139-156.
55. Post R.M., Altshuler L.L., Frye M.A., Suppes T., Rush A.J., Keck P.E. Jr., McElroy S.L., Denicoff K.D., Leverich G.S., Kupka R., Nolen W.A. Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers. Bipolar Disord. 3:2001;259-265.
56. Prien R.F., Caffey E.M. Jr., Klett C.J. Prophylactic efficacy of lithium carbonate in manic-depressive illness. Report of the Veterans Administration and National Institute of Mental Health collaborative study group. Arch Gen Psychiatry. 28:1973;337-341.
57. Prien R.F., Klett C.J., Caffey E.M. Jr. Lithium carbonate and imipramine in prevention of affective episodes. A comparison in recurrent affective illness. Arch Gen Psychiatry. 29:1973;420-425.
58. Sachs G.S., Grossman F., Ghaemi S.N., Okamoto A., Bowden C.L. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry. 159:2002;1146-1154.
59. Sachs G.S., Lafer B., Stoll A.L., Banov M., Thibault A.B., Tohen M., Rosenbaum J.F. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry. 55:1994;391-393.
60. Schou M. The combat of non-compliance during prophylactic lithium treatment. Acta Psychiatr Scand. 95:1997;361-363.
61. Schumann C., Lenz G., Berghofer A. Non-adherence with long-term prophylaxis: a 6-year naturalistic follow-up study of affectively ill patients. Psychiatry Res. 89:1999;247-257.
62. Shopsin B., Gershon S., Thompson H., Collins P. Psychoactive drugs in mania. A controlled comparison of lithium carbonate, chlorpromazine, and haloperidol. Arch Gen Psychiatry. 32:1975;34-42.
63. Simon G.E., Unutzer J. Health care utilization and costs among patients treated for bipolar disorder in an insured population. Psychiatr Serv. 50:1999;1303-1308.
64. Soares J.C. Recent advances in the treatment of bipolar mania, depression, mixed states, and rapid cycling. Int Clin Psychopharmacol. 15:2000;183-196.
65. Solomon D.A., Keitner G.I., Ryan C.E., Miller I.W. Lithium plus valproate as maintenance polypharmacy for patients with bipolar I disorder: a review. J Clin Psychopharmacol. 18:1998;38-49.
66. Stahl S.M. Essential Psychopharmacology: Neuroscientific Basis and Practical Application. 2000;Cambridge University Press, Cambridge.
67. Stefansson J.G., Lindal E., Bjornsson J.K., Guomundsdottir A. Lifetime prevalence of specific mental disorders among people born in Iceland in 1931. Acta Psychiatr Scand. 84:1991;142-149.
68. Strakowski S.M., McElroy S.L., Keck P.E. Jr., West S.A. Suicidality among patients with mixed and manic bipolar disorder. Am J Psychiatry. 153:1996;674-676.
69. Tohen M., Zhang F., Taylor C.C., Burns P., Zarate C., Sanger T., Tollefson G. A meta-analysis of the use of typical antipsychotic agents in bipolar disorder. J Affect Disord. 65:2001;85-93.
70. Tondo L., Baldessarini R.J., Hennen J., Floris G. Lithium maintenance treatment of depression and mania in bipolar I and bipolar II disorders. Am J Psychiatry. 155:1998;638-645.
71. Woods S.W. The economic burden of bipolar disease. J Clin Psychiatry. 61:(Suppl. 13):2000;38-41.